---
title: "Top Insmed Executive Executes Major Multi-Million Dollar Stock Move"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295744066.md"
description: "Insmed's COO Roger Adsett sold 239,850 shares worth $31.96 million on August 12, 2026. This follows strong Q2 results where revenue beat expectations due to BRINSUPRI launch and ARIKAYCE growth, prompting raised sales estimates. Despite bullish analyst views from pipeline momentum, TipRanks' AI assigns a Neutral rating citing large losses and cash burn. Technicals show a bearish trend, though the current signal is Strong Buy."
datetime: "2026-08-13T02:15:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295744066.md)
  - [en](https://longbridge.com/en/news/295744066.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295744066.md)
generator: "portal-rs"
---

# Top Insmed Executive Executes Major Multi-Million Dollar Stock Move

New insider activity at Insmed ( (INSM) ) has taken place on August 12, 2026.

Insmed’s Chief Operating Officer, Roger Adsett, has executed a significant stock transaction, selling 239,850 shares of Insmed stock in a move totaling $31,964,809 in value. This sizable sale by a key executive will likely draw investor attention as markets assess what the transaction may signal about insider sentiment and the company’s future prospects.

Insmed shares reacted to a strong Q2 report with revenue beating expectations, driven by a rapid U.S. launch of BRINSUPRI and continued growth in ARIKAYCE. Management raised peak sales estimates for its three lead programs to a combined level above prior goals, citing robust launch enthusiasm, positive TPIP PAH data, and a broad Phase 3 and early‑stage pipeline that supports long-term growth, which underpinned bullish analyst views and fresh coverage.

**Spark’s Take on INSM Stock**

According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.

The score is primarily driven by mixed financial performance—strong revenue growth and improving margins/balance-sheet leverage but still very large losses and heavy cash burn. Earnings call factors are a major offset, with raised 2026 revenue guidance and strong launch/pipeline momentum supporting a higher outlook. Technicals and valuation weigh on the score due to a bearish trend below key moving averages and a negative P/E with no dividend support.

To see Spark’s full report on INSM stock,  
 click here. 

**More about Insmed**

**YTD Price Performance:** -23.83%

**Average Trading Volume:** 3,790,046

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** $29.43B

### Related Stocks

- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)

## Related News & Research

- [Insmed director Melvin Sharoky, M.D. sells 5,000 shares for $637,650](https://longbridge.com/en/news/296395374.md)
- [13,000 Shares in Insmed, Inc. $INSM Purchased by S&CO Inc.](https://longbridge.com/en/news/296021707.md)
- [Insmed COO Roger Adsett sells 239,850 shares for $31.97 million](https://longbridge.com/en/news/295709972.md)
- [$1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/295430649.md)
- [Is Insmed (INSM) Cheap Following The EMBARC Partnership And Upcoming TPIP Data?](https://longbridge.com/en/news/290887115.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**